We count visits as totals without cookies, and never follow you from one day to the next. If you accept, we also use cookies to see how people use this site, so we can improve it. Privacy policy
Last close (USD)52.42+3.01 (+6.09%)as of 4 Nov 2026
Funds that hold it3One fund per scheme
Held through a master fund30 buy the stock themselves
Largest weight in a single fund3.61%Of that fund's NAV
Median weight2.61%Half the funds hold more than this
What does TVTX do
Travere Therapeutics, Inc.
Develops and sells drugs for rare kidney diseases. Most revenue comes from drugs for kidney inflammation and rare kidney syndromes
FILSPARITHIOLACHENODAL
Which funds let you invest in TVTX
Sorted by weight held, largest first
Investors in Thailand can buy TVTX through 3 mutual funds open to retail investors. Most of them (3 funds) don't buy the stock themselves. Instead they invest in a master fund abroad, which in turn holds TVTX.
The many funds holding less than 3% are usually index funds holding at market weight · Funds holding more than 8% have deliberately chosen a large position
How many funds each AMC holds it through
DAOLINV
How Thai money reaches TVTX
3 master funds
Master fund
Thai funds using this route
Master fund's TVTX weight
Janus Henderson Horizon Biotechnology Fund
1
3.61%
several master funds (JHHBIU2 LX, ARKG US)
1
2.61%
several master funds
1
1.22%
Data sourcesFunds that buy the stock themselves: top 5 holdings from the AMC's fact sheet as of 30 Sep 2026 · Funds that invest through a master fund: the master fund's portfolio from its issuer's fact sheet or prospectus · Each scheme counts as one fund · Share price: Market data · Financial statements: SEC EDGAR · Ratios: Market data · Weights are as of the report date, and funds can change their portfolios at any time · Investing involves risk. This is not investment advice.
Showing 3 of 3 funds you can buy · The full list is in the Expert view · Latest weights from portfolio reports, and funds can change their portfolios at any time · Past performance is not a guarantee of future performance
Valuation and key ratios
Travere Therapeutics, Inc. · NASDAQ · Fiscal year ends in January
Market cap4.9B USD0.09 billion shares
P/EN/AFY2025 EPS is negative
Forward P/E36.4xBased on forecast 12-month earnings
P/S7.6x
EV/EBITDA827.2x
Dividend yield0.00%0.00 USD per share a year
ROE−29.4%Net profit ÷ shareholders' equity
Debt to equity (D/E)0.00xInterest-bearing debt
Beta1.12Against the S&P 500
Gross margin97.8%FY2025
Operating margin−12.8%FY2025
Net margin−5.3%FY2025
Price ratios use the latest close shown on this page · Forward P/E, P/S and EV/EBITDA from Market data · Beta from 5 years of monthly returns · Total dividends over the last 12 months
Company health made simple
From the FY2025 statements
Sales growth38.9%Fast growth
Yearly average over the last 4 years · Latest annual sales 491.0M USD
Profit from sales−5%Thin margin
For every 100 dollars of sales, about −5 dollars is left as net profit
Dividend0.00%No dividend
Per year, relative to the share price · Tech stocks tend to pay little because they reinvest their profits
1-year share price+53.6%Up
Now 22.4% below its 1-year high
A rise or fall in the share price doesn't move a fund by the same amount — a fund is affected only in proportion to how much it holds
Financial statements
Revenue grows 38.9% a year on average · EPS grows N/A a year on average
Annual · last 5 fiscal years
Revenue and net profit
FY2021132.0M USD−180.0M USD
FY2022109.0M USD−278.0M USD
FY2023145.0M USD−111.0M USD
FY2024233.0M USD−322.0M USD
FY2025491.0M USD−26.0M USD
Total revenue
Net profit
Quarterly · last 5 quarters
Revenue and net profit
Q2 FY2025114.0M USD−13.0M USD
Q3 FY2025165.0M USD26.0M USD
Q4 FY2025130.0M USD3.0M USD
Q1 FY2026127.0M USD−37.0M USD
Q2 FY2026170.0M USD−35.0M USD
Annual income statement, balance sheet and cash flow
Item (USD)
FY2021
FY2022
FY2023
FY2024
FY2025
Total revenue
132.0M USD
109.0M USD
145.0M USD
233.0M USD
491.0M USD
Gross profit
128.0M USD
105.0M USD
134.0M USD
225.0M USD
480.0M USD
Operating profit
Free cash flow = operating cash flow − capital expenditure · A cell showing N/A is an item the statement doesn't report, not a zero · Source: SEC EDGAR
Technical analysis
Closed at 52.42 USD on 4 Nov 2026
Daily trendLeaning downScore −0.40 on a scale of −1 to +1 · 1254 bars
RSI(14)
47.2
ADX(14)
34.8
Position in the price range
17%
Weekly trendSidewaysScore 0.10 on a scale of −1 to +1 · 262 bars
RSI(14)
49.5
ADX(14)
39.0
Position in the price range
63%
Monthly trendClear uptrendScore 1.00 on a scale of −1 to +1 · 61 bars
RSI(14)
63.2
ADX(14)
42.4
Position in the price range
76%
Moving averages (daily)
Period
SMA
EMA
Price vs line
10 days
50.63
50.88
Above
20 days
51.26
52.13
Above
50 days
58.12
55.25
Below
100 days
58.32
54.60
Below
200 days
Indicators (daily)
Indicator
Value
Signal
RSI(14)
47.24
Down
MACD(12,26)
−1.95
Down
ADX(14)
34.80
Neutral
ATR(14) % of price
1.95
Neutral
Support and resistance (weekly pivots)
s349
s250
s1
Trend score = average of the moving-average group and the indicator group ((up signals − down signals) ÷ number of signals) · RSI and ATR use Wilder's method · MACD uses the 12- and 26-period EMA · An ADX of 25 or above counts as a clear trend · Calculated from daily closing prices from Market data · Not investment advice
One fund counted per scheme · Funds investing through a master fund show the master fund's weight in TVTX, not the look-through weight · Past performance is not a guarantee of future performance
DAOL-GIHEALTHDAOL GLOBAL INNOVATIVE HEALTHCARE FUND
ASP-IHEALTH
BCAP-XHEALTHBCAP NEXT GEN Health Fund